SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2119Comment from Barron's this week. Makes one wonder if there's a reasonabIan@SI-5/31/2004
2118[Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias ] >&gtuck-5/25/2004
2117>>Cancer Cell. 2004 May;5(5):443-53. Cathepsin cysteine proteases are etuck-5/25/2004
2116Celgene Aims For Fast FDA Approval Matthew Herper, 07.23.03, 1:20 PM ET NEW YORIcebrg-5/23/2004
2115Re:Sept'03buyrating! hahaha, I'll buy now, maybe!Taut Knot-5/21/2004
2114Millennium Pharmaceuticals "neutral" Wednesday, May 19, 2004 5:30:33 Icebrg-5/19/2004
2113Millennium Pharmaceuticals "market perform" Tuesday, May 18, 2004 2:3Icebrg-5/18/2004
2112Inhibition of acute graft-versus-host disease with retention of graft-versus-tumIcebrg-5/18/2004
2111Miljenko: Thanks! You've expressed your dismay about recent, news-based bescaram(o)uche-5/17/2004
2110"Wasn't this already known?" In part, as speculation. Because triMiljenko Zuanic-5/17/2004
2109Wasn't this already known? <b>Millennium Announces VELCADE(R) (bortezIan@SI-5/17/2004
2108Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitinaIcebrg-5/15/2004
2107Millennium Initiates Phase II Clinical Trial With VELCADE and Rituximab in Patiemopgcw-5/13/2004
2106[Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341tuck-5/7/2004
2105GS: MLNM (IL/N): Q1 sales light. Multiple presentations at ASCO in June. 52-Weemopgcw-5/5/2004
2104[THE PROTEASOME: A SUITABLE ANTINEOPLASTIC TARGET] Nature Reviews Cancer 4, 349tuck-5/4/2004
2103>>The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gtuck-5/4/2004
2102Thanks for the notes. Here's a couple of more impressions of the CC: financArea51-4/30/2004
210104/29/04 cc notes 1.1 q results- - bate V in Europe; V moderate growth in 2 q,software salesperson-4/29/2004
2100Millennium Pharmaceuticals downgraded to "market perform" Wednesday, Icebrg-4/29/2004
2099Millennium Pharmaceuticals downgraded to "neutral" Thursday, April 29Icebrg-4/29/2004
2098<i>Velcade sales came in at $29.6 <b>billion</b></i> Sotom pope-4/28/2004
2097<<Revenues a bit light, …>> Bit light! Right! They didn’t have any Miljenko Zuanic-4/28/2004
2096Either Briefing sure got this one wrong, or the market is delaying its reaction Ian@SI-4/28/2004
2095MLNM Q1 report To me a disappointment was that the only thing that they felt woIcebrg-4/28/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News